NAPA, Calif.--(BUSINESS WIRE)--C21 BioVentures (C21), a TVG Global Life Science Network conference, provides a platform for the life science industry to come together in an intimate environment to hear from leading investors, learn from new business models and to meet face-to-face to get business done.
Delegates at C21 had the opportunity to hear keynote addresses from Mr. Michael Gaito, Managing Director at J.P. Morgan, and Dr. George Scangos, Chief Executive Officer at Biogen Idec, Inc., both offering unique perspectives and expert insight into current issues affecting the biotechnology industry.
In his keynote address titled Financing Biotechnology in 2011 and Beyond, Mr. Gaito offered a cautiously optimistic outlook on the recovery of financial markets in 2011 and their effect on the biotechnology sector. In the address he offered details on how biotechnology companies have supplemented venture capital with venture debt and big pharma venture funds as attractive long-term capital sources. To conclude his presentation, Mr. Gaito outlined the keys to a positive equity environment for biotechnology. The keys include continued strong broader market performance, continued M&A market recovery, and continued positive clinical and regulatory momentum.
On the second day of C21, in his keynote titled Reshaping Biogen Idec: Chapters 1 and 2, Dr. George Scangos, CEO of Biogen Idec, offered a detailed account of the strategy and tactics used to reshape Biogen Idec into a more effective, focused, and ultimately more profitable large biotech company.
"As you know last year the company went through a restructuring process. This was based on my review of the portfolio, where I saw Biogen Idec as a company that was spread too thin across multiple therapeutic areas. We were a mile wide and an inch deep. We needed to focus the company on areas where we had the collection of people, assets and capabilities to be among the leaders in that space. We are a great company and are among the world leaders in some of the things that we do. But we needed to build on that base and stop allocating precious resources to other areas where we had no competitive advantage."
Dr. Scangos went on to show how the transformation is changing internal culture, eliminating unnecessary layers in corporate structure, consolidating sites and building a strong senior management team. The changes have resulted in $300 million in annual savings and a stronger more focused organization.
Dr. Scangos' presentation and several other C21 expert sessions focused on a clear need for capital efficiency, innovative business models and creative partnerships across the industry.
“The C21 BioVentures Conference provides an opportunity for senior executives from early stage biotechnology companies, venture capital firms and large pharmaceutical companies to meet in an atmosphere where business gets done,” said Robert Lee Kilpatrick, Ph.D., a partner with TVG. “We’re pleased to bring together the people who forge the bonds that will shape the future of biopharmaceuticals in an era of dramatic economic, regulatory and scientific change.”
About Technology Vision Group (TVG)
Technology Vision Group LLC (TVG) is the leading networking and business development organization serving the international life sciences industry. Since 1992, TVG has been developing innovative methods to help life science and associated technology companies attract partners and investors, acquire new products and technologies, and achieve a variety of other strategic business development goals.
TVG’s Global Conference Network includes 5 other international conferences:
- BioPartnering Latin AmericaTM (BPL)
- BioPartnering EuropeTM (BPE)
- BioPartnering ChinaTM (BPC)
- BioPartnering North AmericaTM (BPN)
- BioPartnering IndiaTM (BPI)
For more information, please visit: www.techvision.com
Producers
TVG
Hosts
BayBio, BIOCOM
2011 Podium Presenters (As of May 23, 2011)
13therapeutics; ACT Biotech; ADS Biotechnology; Aethion Medical, Inc.; Afraxis, Inc.; Anaphore, Inc.; Apeiron Biologics Gmbh; Applied Integrin Science, Inc.; Aquinox Pharmaceuticals, Inc.; Ascendis Pharma; Biovista, Inc.; Centrose; Chimeros, Inc.; Del Mar Pharmaceuticals; Delpor, Inc.; DermTech International; Embera Neuro Therapeutics; Epic Sciences; EyeCyte, Inc.; Fibralign Corporation; Finox Biotech; Fluxion Biosciences; Fluxome A/S; Formatech, Inc.; Galenea Corporation; Galera Therapeutics; Genentech, Inc.; Hepregen Corporation; ImmunGene; Inagen; Juventas Therapeutics; KAI Pharmaceuticals, Inc.; Kareus Therapeutics LLC; KromaTiD; MannKind Corporation; Mayfield Bioscience, Inc.; MetaSignal Therapeutics, Inc.; Mithridion, Inc.; Molecular Response; Molecular Templates, Inc.; My Mercury Risk, Inc.; NAL Pharmaceuticals Ltd.; NeuroQuest, Inc.; Neurotez, Inc.; NextWave Pharmaceuticals, Nutrition 21, Inc.; Omniox, Inc.; Oncolix, Inc.; Pacific Biosciences; Phoenix PharmaLabs, Inc.; Phyto Biotech Ltd.; Presbia Cooperatief; ProNAi Therapeutics, Inc.; Q Therapeutics, Inc.; Receptos, Ruga Corporation; SARcode Corporation; Savara; SEA Medical Systems; STATegics, Inc.; Susavion Biosciences, Inc.; Trellis Bioscience, Inc.; VetDC, Inc.; Vidasym; Virobay, Inc.; ZaBeCor Pharmaceuticals; Zymeworks
Gold Sponsors
Deloitte; Merck
Silver Sponsors
Aquilo Partners; DLA Piper; Latham & Watkins, LLP; Merrill Datasite; Morrison & Foerster
Conference Sponsors
Aragen Bioscience; Ash Stevens; Colley LLP; CFO Connect; Nature Publishing Group (NPG); Paragon Bioservices
Conference Supporters
AusBiotech; GBI; Silicon Valley Bank; Zoomedia
Media Sponsors
Business Wire, Current Agreements, Current Partnering
Media Supporters
Bio-IT World; Innovaro Pharmalicensing; BioCentury; Larta Institute; Biotechnology Journal; Pharmatching.com; FreeMind; PharmaVOICE; TheScientist
Regional Affiliates
Spanish Association of Biotech Companies (ASEBIO); BioForward; BioNJ; BioNova; Colorado BioScience Association; Georgia Bio; Indiana Health Industry Forum; Life Science Angels; Life Science Association of Manitoba; San Jose BioCenter; Queensland Clinical Trials Network (QCTN)